Horizon Therapeutics Announces the FDA has Granted Priority Review of the Teprotumumab Biologics License Application for Active Thyroid Eye Disease Treatment | oneGRAVESvoice

welcome to oneGRAVESvoice

- a positively charged Graves' disease and thyroid eye disease community.
  • join today!

Horizon Therapeutics Announces the FDA has Granted Priority Review of the Teprotumumab Biologics License Application for Active Thyroid Eye Disease Treatment


Horizon Therapeutics plc today announced that the U.S. Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for teprotumumab, an investigational medicine for the treatment of active thyroid eye disease (TED), and granted it Priority Review designation. The FDA grants Priority Review designation to applications for medicines that have the potential to provide significant improvements in the treatment of serious conditions. Priority Review is associated with an accelerated six-month review period compared to the standard ten-month review period. If approved, teprotumumab would be the first FDA-approved medicine for the treatment of active TED.

“Priority Review for the teprotumumab BLA is another positive step toward our goal to make a difference in the lives of people who are living with active TED – a painful, debilitating and vision-threatening rare disease,” said Timothy Walbert, Chairman, President and Chief Executive Officer, Horizon.

Horizon Therapeutics Announces The FDA Has Granted Priority Review Of The Teprotumumab Biologics License Application For Active Thyroid Eye Disease Treatment
Disclaimer: Horizon supports the mission of oneGRAVESvoice and has provided financial support for this platform. Horizon neither owns or controls this platform, and unless expressly stated otherwise, does not have editorial control over content or responsibility for any other information or services.